Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSPA9 | P38646 | 3/20 | 0.53 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119851 | 1.00 | HSPA5 (0.57) | HSPA5LMNATSHRHSPA9FFAR2 | |
| Hydrochloric Acid SCHEMBL7422746 | 0.98 | HSPA5 (0.56) | HSPA5LMNATSHRHSPA9FFAR2 | |
| SCHEMBL7873389 | 0.89 | HSPA5 (0.53) | HSPA5LMNATSHRHSPA9FFAR2 | |
| SCHEMBL7876872 | 0.83 | LMNA (0.59) | HSPA5LMNATSHRHSPA9FFAR2 | |
| SCHEMBL4119847 | 0.83 | LMNA (0.56) | HSPA5LMNATSHRHSPA9FFAR2 | |
| SCHEMBL23804604 | 0.83 | LMNA (0.59) | HSPA5LMNATSHRHSPA9FFAR2 | |
| SCHEMBL12884426 | 0.81 | LMNA (0.58) | HSPA5LMNATSHRHSPA9FFAR2 | |
| Bromide SCHEMBL11317007 | 0.81 | LMNA (0.57) | HSPA5LMNATSHRHSPA9FFAR2 | |
| Bromide SCHEMBL11310643 | 0.80 | LMNA (0.57) | HSPA5LMNATSHRHSPA9FFAR2 | |
| SCHEMBL7868173 | 0.79 | LMNA (0.56) | HSPA5LMNATSHRHSPA9FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148839-A1 | New pharmaceutical compositions based on anticholinergics and tace-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060148839-A1 | New pharmaceutical compositions based on anticholinergics and tace-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1019386-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-19 | — | — | EP | disclosed |
| US-5919940-A | TERT-LEUCINE-THIAZOL-2-YLAMIDE | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5859253-A | L-TERT-LEUCINE-2-PYRIDYLAMIDE | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-01-12 | — | — | US | disclosed |
| WO-1998038179-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
| EP-0740652-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1998-05-06 | — | — | EP | disclosed |
| US-5747514-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148839-A1 | New pharmaceutical compositions based on anticholinergics and tace-inhibitors | TPSAB1, CMA1, TPSG1 | HSPA5 3822/4885LMNA 1521/4885TSHR 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.